CRVSCorvus Pharmaceuticals, Inc.
Price
+79%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 0% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for CRVS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function.
In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 22, 2026On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), effective as of July 22, 2026.Director or officer change · Form 8-K
- May 14, 2026The trial enrolled 72 patients with moderate-to-severe atopic dermatitis that previously failed one prior topical or systemic therapy. Thirty-five percent of the patients had received a prior systemic therapy.Regulation FD disclosure · Form 8-K
- May 7, 2026Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.